Structure Therapeutics Inc. (GPCR)
Largest Insider Buys in Sector
GPCR Stock Price History Chart
GPCR Stock Performance
About Structure Therapeutics Inc.
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular …
Insider Activity of Structure Therapeutics Inc.
Over the last 12 months, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of Structure Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Structure Therapeutics Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Structure Therapeutics Inc.
| 2024-06-10 | Sale | CHIEF EXECUTIVE OFFICER | 185,000 – | $0 | $0 | -27.53% | ||
| 2024-06-03 | Sale | CHIEF SCIENTIFIC OFFICER | 35,400 – | $0 | $0 | -27.25% |